Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eyantra Ventures' Board approved standalone and consolidated unaudited results for Q2 FY26 and H1 FY26. Standalone revenue surged to ₹1,819.59 lakhs in Q2 FY26 from ₹635.51 lakhs in Q2 FY25, a jump of about 186%. However, standalone net profit fell sharply to ₹4.35 lakhs from ₹34.41 lakhs due to higher purchase and employee costs. On a consolidated basis, revenue was ₹2,294.86 lakhs but the company swung to a net loss of ₹425.53 lakhs in Q2 FY26 versus a profit of ₹34.18 lakhs a year ago, largely dragged by its newly consolidated subsidiary Neuro and Spine Associates, which reported a loss of ₹336.54 lakhs for the quarter. H1 FY26 consolidated net loss stood at ₹785.15 lakhs. The auditor (PRSV & Co LLP) issued an unmodified limited review report.
Strong top-line growth from business expansion and the Neuro and Spine Associates acquisition is positive, but sharply falling margins, consolidated losses, and negative operating cash flows (-₹727 lakhs standalone, -₹1,254 lakhs consolidated) are concerns. Shareholders should watch whether the healthcare subsidiary can turn profitable, as it currently dominates the consolidated loss.